Inogen, Inc (NASDAQ:INGN - Get Free Report) shares passed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $6.65 and traded as high as $7.50. Inogen shares last traded at $7.42, with a volume of 247,505 shares trading hands.
Analyst Upgrades and Downgrades
INGN has been the subject of several research reports. Needham & Company LLC raised Inogen from a "hold" rating to a "moderate buy" rating and set a $12.00 target price for the company in a report on Thursday, May 22nd. B. Riley initiated coverage on Inogen in a report on Monday, June 16th. They issued a "buy" rating and a $14.00 target price for the company. Finally, Stifel Nicolaus reduced their target price on Inogen from $10.00 to $7.00 and set a "hold" rating for the company in a report on Thursday, May 8th.
Check Out Our Latest Analysis on INGN
Inogen Stock Performance
The business has a 50 day moving average price of $6.65 and a 200-day moving average price of $8.08.
Inogen (NASDAQ:INGN - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The medical technology company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.27. Inogen had a negative return on equity of 14.76% and a negative net margin of 8.08%. The firm had revenue of $82.28 million during the quarter, compared to the consensus estimate of $79.57 million. As a group, research analysts anticipate that Inogen, Inc will post -1.73 earnings per share for the current year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in INGN. Strs Ohio purchased a new position in Inogen in the first quarter valued at about $468,000. Acadian Asset Management LLC increased its position in shares of Inogen by 35.7% during the first quarter. Acadian Asset Management LLC now owns 1,028,322 shares of the medical technology company's stock worth $7,325,000 after acquiring an additional 270,453 shares during the last quarter. Jane Street Group LLC purchased a new stake in shares of Inogen during the first quarter worth about $463,000. Goldman Sachs Group Inc. increased its position in shares of Inogen by 16.9% during the first quarter. Goldman Sachs Group Inc. now owns 284,180 shares of the medical technology company's stock worth $2,026,000 after acquiring an additional 41,002 shares during the last quarter. Finally, Integrated Wealth Concepts LLC purchased a new stake in shares of Inogen during the first quarter worth about $85,000. Institutional investors and hedge funds own 89.94% of the company's stock.
Inogen Company Profile
(
Get Free Report)
Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
See Also
Before you consider Inogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inogen wasn't on the list.
While Inogen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
